{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:26:40Z","timestamp":1791052000084,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2004,5,5]],"date-time":"2004-05-05T00:00:00Z","timestamp":1083715200000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2004,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The declining incidence of AIDS\u2010related opportunistic diseases among people with HIV infection has shifted the focus of clinical management to prevention and treatment of comorbidities such as chronic liver disease. The increased risk of hepatitis C virus (HCV)\u2010related advanced liver disease in people with HIV infection makes early HCV diagnosis a priority. To assess HCV prevalence and predictors of HIV\/HCV coinfection, we have conducted a retrospective analysis of people enrolled in the CAESAR (Canada, Australia, Europe, South Africa) study, a multinational randomized placebo\u2010controlled study of the addition of lamivudine to background antiretroviral therapy. The impact of HCV on HIV disease progression was also examined. Anti\u2010HCV antibody testing on 1649 CAESAR study participants demonstrated a HIV\/HCV coinfection prevalence of 16.1%, which varied from 1.9% in South Africa to 48.6% in Italy. The strongest predictor of HIV\/HCV coinfection was HIV exposure category (<jats:italic>P<\/jats:italic>&lt;0.0001), with odds ratios (ORs) compared to homosexual as follows: injecting drug use (IDU), 365 [95% confidence interval (CI): 179\u2013742]; transfusion or blood products, 32.2 (95% CI: 15.2\u201367.6); homosexual and IDU, 22.9 (95% CI: 8.5\u201362.1). The prevalence of HIV\/HCV was low (3.7%) among homosexual men without reported IDU. Other predictors of HIV\/HCV coinfection were alanine aminotransferase (ALT), country of residence, ethnicity and stage of HIV disease. A history of IDU or ALT \u226540\u2003U\/L at baseline had a positive predictive value (PPV) of 35%, negative predictive value (NPV) of 96%, sensitivity of 82% and specificity of 71% for HIV\/HCV coinfection. HIV disease progression was similar in HIV monoinfected and HIV\/HCV coinfected patients. People with HIV and a history of IDU or elevated liver function tests should be targeted for HCV testing. The low prevalence of HIV\/HCV coinfection among homosexual men without a history of IDU suggests low efficiency of sexual HCV transmission.<\/jats:p>","DOI":"10.1111\/j.1468-1293.2004.00207.x","type":"journal-article","created":{"date-parts":[[2004,5,5]],"date-time":"2004-05-05T11:50:54Z","timestamp":1083757854000},"page":"174-179","source":"Crossref","is-referenced-by-count":89,"title":["HIV and hepatitis C coinfection within the CAESAR study"],"prefix":"10.1111","volume":"5","author":[{"given":"J","family":"Amin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Skidmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DA","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GJ","family":"Dore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,5,5]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"397","article-title":"HCV RNA levels and HIV infection","volume":"88","author":"Telfer PT","year":"1994","journal-title":"evidence for a viral interaction in haemophilic patients"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7104.333"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb08312.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(98)80341-3"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(97)80001-3"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01691375"},{"key":"e_1_2_6_8_2","first-page":"602","article-title":"Natural history of hepatitis C virus infection in multitransfused hemophiliacs","volume":"6","author":"Eyster ME","year":"1993","journal-title":"effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study"},{"key":"e_1_2_6_9_2","first-page":"562","article-title":"Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection","volume":"33","author":"Graham CS","year":"2001","journal-title":"a meta-analysis"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/172.6.1503"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199804000-00006"},{"key":"e_1_2_6_12_2","first-page":"1800","article-title":"Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV\u20101 and hepatitis C virus coinfection","volume":"356","author":"Greub G","year":"2000","journal-title":"the Swiss HIV Cohort Study"},{"key":"e_1_2_6_13_2","first-page":"2","article-title":"Opportunistic infections","volume":"7","author":"Furrer H","year":"2002","journal-title":"an update"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007506617734"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/318501"},{"key":"e_1_2_6_16_2","first-page":"167","article-title":"Association between hepatitis C infection and other infectious diseases","volume":"98","author":"El Serag HB","year":"2003","journal-title":"a case for targeted screening?"},{"key":"e_1_2_6_17_2","first-page":"1413","article-title":"Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine\u2010containing regimens for patients with HIV\u20101 infection","volume":"349","author":"CAESAR Co\u2010ordinating Committee","year":"1997","journal-title":"the CAESAR trial"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1601-0825.2002.00007.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/17.1.117"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05924.x"},{"key":"e_1_2_6_21_2","first-page":"137","article-title":"Transmission of hepatitis C virus","volume":"18","author":"MacDonald M","year":"1996","journal-title":"rates, routes, and cofactors"},{"key":"e_1_2_6_22_2","first-page":"227","article-title":"Risk factors for hepatitis C virus infection in blood donors","volume":"157","author":"Kaldor JM","year":"1992","journal-title":"a case-control study"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0270-9139(03)80603-1"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-200112000-00010"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/170.2.433"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1086\/339867"},{"key":"e_1_2_6_27_2","first-page":"41","article-title":"Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV","volume":"29","author":"Aceti A","year":"2002","journal-title":"the role of hepatitis B and C virus infection"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/317449"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.1.74"},{"key":"e_1_2_6_30_2","first-page":"182","article-title":"Hepatotoxicity associated with nevirapine or efavirenz\u2010containing antiretroviral therapy","volume":"35","author":"Sulkowski MS","year":"2002","journal-title":"role of hepatitis C and B infections"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200012220-00011"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.2.199"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(02)00074-0"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2004.00207.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2004.00207.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T04:55:04Z","timestamp":1696913704000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2004.00207.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["10.1111\/j.1468-1293.2004.00207.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2004.00207.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}